United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
United Therapeutics (UTHR) has announced that President and COO Michael Benkowitz will present at the TD Cowen 45th Annual Health Care Conference in Boston. The fireside chat session is scheduled for March 3, 2025, from 1:50 p.m. to 2:20 p.m. EST.
The presentation will be accessible through a live webcast on the company's website, with a recorded version available for 90 days afterward. United Therapeutics, operating as a public benefit (PBC), focuses on developing novel pharmaceutical therapies and technologies to expand transplantable organ availability.
The company emphasizes its unique position as the first publicly-traded biotech/pharmaceutical PBC, highlighting its commitment to innovation for unmet medical needs while maintaining a dual focus on patient care and stakeholder benefits.
United Therapeutics (UTHR) ha annunciato che il Presidente e COO Michael Benkowitz parteciperà al 45° Conferenza Annuale sulla Salute di TD Cowen a Boston. La sessione di discussione è programmata per il 3 marzo 2025, dalle 13:50 alle 14:20 EST.
La presentazione sarà accessibile tramite un webcast in diretta sul sito web dell'azienda, con una versione registrata disponibile per 90 giorni dopo. United Therapeutics, operando come Public Benefit Corporation (PBC), si concentra sullo sviluppo di nuove terapie e tecnologie farmaceutiche per aumentare la disponibilità di organi trapiantabili.
L'azienda sottolinea la sua posizione unica come prima PBC biotech/farmaceutica quotata in borsa, evidenziando il suo impegno per l'innovazione in risposta a bisogni medici insoddisfatti, mantenendo al contempo un duplice focus sulla cura dei pazienti e sui benefici per gli stakeholder.
United Therapeutics (UTHR) ha anunciado que el Presidente y COO Michael Benkowitz presentará en la 45ª Conferencia Anual de Salud de TD Cowen en Boston. La sesión de charla está programada para el 3 de marzo de 2025, de 1:50 p.m. a 2:20 p.m. EST.
La presentación será accesible a través de una transmisión en vivo en el sitio web de la empresa, con una versión grabada disponible por 90 días después. United Therapeutics, operando como una Corporación de Beneficio Público (PBC), se centra en desarrollar nuevas terapias y tecnologías farmacéuticas para aumentar la disponibilidad de órganos trasplantables.
La empresa enfatiza su posición única como la primera PBC biotecnológica/farmacéutica que cotiza en bolsa, destacando su compromiso con la innovación para necesidades médicas no satisfechas, mientras mantiene un enfoque dual en la atención al paciente y los beneficios para los interesados.
United Therapeutics (UTHR)는 사장 겸 COO인 Michael Benkowitz가 보스턴에서 열리는 TD Cowen 제45회 연례 의료 회의에서 발표할 것이라고 발표했습니다. 화상 대화 세션은 2025년 3월 3일 오후 1시 50분부터 2시 20분 EST까지 예정되어 있습니다.
발표는 회사 웹사이트에서 실시간 웹캐스트를 통해 접근할 수 있으며, 이후 90일 동안 녹화된 버전이 제공됩니다. United Therapeutics는 공공 이익 법인(PBC)으로 운영되며, 이식 가능한 장기 가용성을 확대하기 위해 새로운 제약 치료법과 기술을 개발하는 데 집중하고 있습니다.
회사는 상장된 최초의 생명공학/제약 PBC로서의 독특한 입장을 강조하며, 충족되지 않은 의료 요구를 위한 혁신에 대한 헌신을 강조하면서 환자 치료와 이해관계자 이익에 대한 이중 초점을 유지하고 있습니다.
United Therapeutics (UTHR) a annoncé que le Président et COO Michael Benkowitz présentera lors de la 45ème Conférence Annuelle sur la Santé de TD Cowen à Boston. La session de discussion est prévue pour le 3 mars 2025, de 13h50 à 14h20 EST.
La présentation sera accessible via un webcast en direct sur le site de l'entreprise, avec une version enregistrée disponible pendant 90 jours par la suite. United Therapeutics, opérant en tant que Corporation de Bénéfice Public (PBC), se concentre sur le développement de nouvelles thérapies et technologies pharmaceutiques pour accroître la disponibilité des organes transplantables.
L'entreprise souligne sa position unique en tant que première PBC biopharmaceutique cotée en bourse, mettant en avant son engagement envers l'innovation pour les besoins médicaux non satisfaits tout en maintenant un double focus sur les soins aux patients et les avantages pour les parties prenantes.
United Therapeutics (UTHR) hat angekündigt, dass Präsident und COO Michael Benkowitz auf der 45. jährlichen Gesundheitskonferenz von TD Cowen in Boston präsentieren wird. Die Diskussionsrunde ist für den 3. März 2025 von 13:50 bis 14:20 Uhr EST angesetzt.
Die Präsentation wird über einen Live-Webcast auf der Unternehmenswebsite zugänglich sein, mit einer aufgezeichneten Version, die 90 Tage lang verfügbar ist. United Therapeutics, das als Public Benefit Corporation (PBC) tätig ist, konzentriert sich auf die Entwicklung neuartiger pharmazeutischer Therapien und Technologien zur Erweiterung der Verfügbarkeit von transplantierbaren Organen.
Das Unternehmen betont seine einzigartige Position als erste börsennotierte Biotech/Pharma-PBC und hebt sein Engagement für Innovationen zur Deckung unerfüllter medizinischer Bedürfnisse hervor, während es gleichzeitig einen dualen Fokus auf die Patientenversorgung und die Vorteile für die Stakeholder beibehält.
- None.
- None.
The session will take place on Monday, March 3, 2025, from 1:50 p.m. to 2:20 p.m., Eastern Standard Time, and can be accessed via a live webcast on the United Therapeutics website at https://ir.unither.com/events-and-presentations. An archived, recorded version of the session will be available approximately 24 hours after the session ends and can be accessed for 90 days.
United Therapeutics: Enabling Inspiration
At United Therapeutics, our vision and mission are one. We use our enthusiasm, creativity, and persistence to innovate for the unmet medical needs of our patients and to benefit our other stakeholders. We are bold and unconventional. We have fun, we do good. We are the first publicly-traded biotech or pharmaceutical company to take the form of a public benefit corporation (PBC). Our public benefit purpose is to provide a brighter future for patients through (a) the development of novel pharmaceutical therapies; and (b) technologies that expand the availability of transplantable organs.
You can learn more about what it means to be a PBC here: unither.com/pbc.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, our efforts to innovate for the unmet medical needs of our patients, to benefit our other stakeholders, and to pursue our public benefit purpose of developing novel pharmaceutical therapies and technologies that expand the availability of transplantable organs. These forward-looking statements are subject to certain risks and uncertainties, such as those described in our periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language, and risk factors set forth in our periodic reports and documents filed with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. We claim the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We are providing this information as of February 24, 2025, and assume no obligation to update or revise the information contained in this press release whether because of new information, future events or any other reason.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224087403/en/
For Further Information Contact:
Dewey Steadman at (202) 919-4097 (media/investors)
Harry Silvers at (301) 578-1401 (investors)
https://ir.unither.com/contact-ir
Source: United Therapeutics Corporation
FAQ
When is United Therapeutics (UTHR) presenting at the TD Cowen Healthcare Conference 2025?
How can investors access UTHR's presentation at the TD Cowen conference?
What is United Therapeutics' (UTHR) status as a public benefit ?
Who will represent UTHR at the TD Cowen Healthcare Conference 2025?
